BioSpace News Archive

Asieris Pharmaceuticals, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, today announced that Australian regulatory authorities have approved its Phase I clinical trial of APL-1501

Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share.

Synthetic biology market has evolved on the back of surging industry interest worldwide on the profound capabilities it is said to possess, mainly by virtue of redesigning biological components and systems.

Sodium phenylbutyrate drugs are prescribed for adjunctive therapy in the chronic management of urea cycle disorders.

The surging cases of neurological disorders and traumatic brain injuries are the key factors boosting the global external ventricular drain market growth.

Ataxia is a degenerative disease of the nervous system, which causes movement disorder. Patients of ataxia have issues while moving parts of body or the muscles in the arms and legs without coordination

Akorn, a leading specialty pharmaceutical company, today announced the appointment of its new Board of Directors. “Akorn’s new shareholders have appointed a strong board of independent pharmaceutical industry and finance professionals with a mandate to steward the Company towards long-term value creation,” said Robert Webst

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m.

CStone Pharmaceuticals (“CStone”, HKEX: 2616) announced today a licensing agreement with LegoChem Biosciences, Inc. (“LCB”, KOSDAQ:141080), for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate (“ADC”).

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced new data have been published today in The Lancet Oncology.